Background:

AST2818 mesylate is an EGFR inhibitor.

AST2818 mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation[1].

[1]. Y.Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial. J Thorac Oncol. 2017 Nov, 12(11): S2138.